v3.25.4
LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Feb. 28, 2025
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                        
Net loss $ 1,850,493 $ 1,981,293 $ 15,941,328 $ 765,710 $ 216,269 $ 96,923 $ 230,970 $ 19,773,114 $ 544,162      
Net cash outflows from operations               3,995,647 $ 744,755      
Accumulated deficit 22,550,347     2,777,233       22,550,347   $ 2,777,233    
Working capital deficit 11,457,377             11,457,377        
Cash $ 1,948,271     3,633       $ 1,948,271   3,633    
Business combination proceeds                       $ 265,827
Business combination additional amount                       $ 3,000,000
Aspire Biopharma Inc [Member]                        
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                        
Net loss                   1,309,872 $ 359,070  
Net cash outflows from operations                   265,186 (11,136)  
Accumulated deficit       2,777,233           2,777,233 1,467,361  
Cash       $ 3,633           $ 3,633 $ 11,174